Regeneron Pharmaceuticals Inc. buy PapaSmurf
Summary
This prediction ended on 19.12.19 with a price of €335.35. The prediction had a final performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -2.090% | -2.090% | 31.525% | 85.709% |
iShares Core DAX® | 2.291% | 2.984% | 20.344% | 20.143% |
iShares Nasdaq 100 | 1.336% | -0.196% | 25.550% | 37.734% |
iShares Nikkei 225® | 1.132% | 2.488% | 13.163% | 1.261% |
iShares S&P 500 | 1.272% | 1.334% | 24.544% | 40.521% |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren